視網膜靜脈阻塞治療市場規模、佔有率和成長分析（按疾病類型、治療類型、藥物類型、最終用戶和地區）- 產業預測 2025-2032

視網膜靜脈阻塞治療市場規模預計在 2023 年達到 24.3 億美元，到 2032 年將從 2024 年的 25.9 億美元擴大到 42.5 億美元，在預測期內（2025-2032 年）的複合年成長率為 6.4%。

視網膜靜脈阻塞 (RVO) 治療市場正在經歷顯著成長，這得益於 RVO 患病率的不斷上升以及易患該疾病的老齡化人口。 RVO 是一種視網膜血管疾病，如果不及時治療，會導致視力喪失。市場提供各種解決方案，包括藥物、雷射和手術治療，主要專注於改善血液循環和減少黃斑部水腫。抗 VEGF 藥物在治療血管異常發育方面尤其受歡迎。北美和歐洲等地區憑藉其先進的醫療保健體系引領市場擴張，而亞太地區則因醫療保健意識的增強而迅速崛起。持續的研究投入、創新的診斷方法和個人化的治療方法將進一步推動市場成長，改善病患照護和治療效果。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管格局
• 專利分析

視網膜靜脈阻塞治療市場規模（依疾病類型及複合年成長率）（2025-2032）

• 市場概況
• 視網膜中央靜脈阻塞 (CRVO)
• 視網膜分支靜脈阻塞症(BRVO)

視網膜靜脈阻塞治療市場規模（依治療類型及複合年成長率）（2025-2032）

• 市場概況
• 抗VEGF
• 皮質類固醇
• 雷射治療

視網膜靜脈阻塞治療市場規模（依藥物類型及複合年成長率） (2025-2032)

• 市場概況
• 品牌
• 非專利的

視網膜靜脈阻塞治療市場規模（依最終用戶和複合年成長率） (2025-2032)

• 市場概況
• 醫院
• 眼科門診
• 門診手術中心（ASC）
• 零售藥局

視網膜靜脈阻塞治療市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• AbbVie Inc.（USA）
• Roche（Switzerland）
• Regeneron Pharmaceuticals, Inc.（USA）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• Alimera Sciences（USA）
• Aerie Pharmaceuticals, Inc.（USA）
• Kodiak Sciences Inc.（USA）
• Chugai Pharmaceutical Co., Ltd.（Japan）
• Taiwan Liposome Company, Ltd.（Taiwan）
• Graybug Vision, Inc.（USA）
• Pfizer Inc.（USA）
• IRIDEX Corporation（USA）
• Lumenis（Israel）
• Nidek Co., Ltd.（Japan）
• Annexin Pharmaceuticals AB（Sweden）
• Outlook Therapeutics, Inc.（USA）
• CalciMedica Inc.（USA）
• F. Hoffmann-La Roche AG（Switzerland）
• Samsung Bioepis（South Korea）

結論和建議

Retinal Vein Occlusion Treatment Market size was valued at USD 2.43 billion in 2023 and is poised to grow from USD 2.59 billion in 2024 to USD 4.25 billion by 2032, growing at a CAGR of 6.4% during the forecast period (2025-2032).

The retinal vein occlusion (RVO) treatment market is experiencing significant growth, fueled by the rising prevalence of RVO and an aging population susceptible to this disorder. RVO, a prevalent retinal vascular issue, can lead to vision impairment if untreated. The market offers a variety of solutions, including medications, laser therapy, and surgical options, primarily focusing on enhancing blood circulation and reducing macular edema. Anti-VEGF medications are particularly favored for managing abnormal blood vessel development. Regions like North America and Europe lead in market expansion due to advanced healthcare systems, while the Asia-Pacific region is rapidly emerging, driven by increased healthcare awareness. Continuous research investment, innovative diagnostics, and personalized treatment approaches are set to further propel market growth, enhancing patient care and outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Retinal Vein Occlusion Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Retinal Vein Occlusion Treatment Market Segments Analysis

Global Retinal Vein Occlusion Treatment Market is segmented by Disease Type, Treatment Type, Medication Type, End-user and region. Based on Disease Type, the market is segmented into Central Retinal Vein Occlusion (CRVO) and Branch Retinal Vein Occlusion (BRVO). Based on Treatment Type, the market is segmented into Anti-VEGF, Corticosteroid Drugs and Laser Therapy. Based on Medication Type, the market is segmented into Branded and Generics. Based on End-user, the market is segmented into Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers (ASC) and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Retinal Vein Occlusion Treatment Market

The market for retinal vein occlusion treatment is propelled by various influential factors, including the increasing prevalence of eye disorders worldwide, a rising elderly demographic, enhanced comprehension of ocular conditions, and the expansion of healthcare infrastructures. Additionally, technological innovations and the development of new therapies significantly boost market growth. The existence of a strong drug pipeline, along with recent drug approvals, plays a vital role in this upward trend. As cases of retinal vein occlusion continue to surge and research on effective treatments intensifies, there is potential for significant market expansion, opening avenues for the adoption of cutting-edge therapeutic solutions for this condition.

Restraints in the Retinal Vein Occlusion Treatment Market

The Retinal Vein Occlusion Treatment market encounters a significant challenge due to a lack of long-term clinical evidence. The effectiveness and safety of various treatment options compared to conventional therapies require more comprehensive evaluation. This uncertainty can hinder the adoption of newer therapies, as both healthcare professionals and patients may be hesitant to embrace treatments that lack robust, long-term studies. Furthermore, the dependence on existing treatments may continue as practitioners seek reassurance about the outcomes of emerging options. Consequently, addressing this restraint is essential for promoting growth and acceptance within the Retinal Vein Occlusion Treatment market.

Market Trends of the Retinal Vein Occlusion Treatment Market

The Retinal Vein Occlusion Treatment market is witnessing significant growth, primarily fueled by the rising prevalence of the condition among the aging population. As more individuals enter older age brackets, the incidence of retinal vein occlusion is expected to increase, necessitating innovative and effective treatment options. This trend is prompting healthcare providers and pharmaceutical companies to develop advanced therapies, including anti-VEGF injections and laser treatments, to cater to the growing patient demographic. As awareness and diagnosis improve, coupled with advancements in treatment modalities, the market is set to expand further, offering lucrative opportunities for stakeholders in the ophthalmology sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Retinal Vein Occlusion Treatment Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Central Retinal Vein Occlusion (CRVO)
• Branch Retinal Vein Occlusion (BRVO)

Global Retinal Vein Occlusion Treatment Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Anti-VEGF
• Corticosteroid Drugs
• Laser Therapy

Global Retinal Vein Occlusion Treatment Market Size by Medication Type & CAGR (2025-2032)

• Market Overview
• Branded
• Generics

Global Retinal Vein Occlusion Treatment Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers (ASC)
• Retail Pharmacies

Global Retinal Vein Occlusion Treatment Market Size & CAGR (2025-2032)

• North America (Disease Type, Treatment Type, Medication Type, End-user)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, Medication Type, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, Medication Type, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, Medication Type, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, Medication Type, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alimera Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerie Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chugai Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taiwan Liposome Company, Ltd. (Taiwan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Graybug Vision, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IRIDEX Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lumenis (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nidek Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Annexin Pharmaceuticals AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Outlook Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CalciMedica Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations